Default company panoramic image
C0b145c6 b176 40a9 9e9c 46ea26a272ac

Promosome LLC

Promosome licenses and employs synthetic biology tools which increase protein production yields, enhance purity and likely provide long-term clinical benefits.

  • Stage $3M in TTM Revenue
  • Industry Biotechnology
  • Location San Diego, CA, US
  • Currency USD
  • Founded June 2003
  • Employees 16
  • Website

Company Summary

Promosome specializes in innovative technologies related to the translation component of protein production. Its products boost production capacity by increasing expression, secretion, and yield of full-length proteins as well as by enhancing downstream efficiencies. It generates revenues from license fees, milestones and royalty arrangements. Promosome has developed a portfolio of therapeutic products (nucleic acid therapeutics, re-engineered hard-to-express proteins, and biosimilars/biobetters) which are available for partnering and commercialization.


  • Mr. LeMasters joined Promosome in July, 2015. Most recently, he was Co-founder and CBO of Tragara Pharmaceuticals, a clinical-stage cancer therapeutics company. Mr. LeMasters also served as Co-founder and CBO of Cabrellis Pharmaceuticals, Inc., where he negotiated its successful acquisition by Pharmion Corporation for $104 million, and as VP, Corp Dev of Conforma Therapeutics, where he negotiated its sale to Biogen IDEC for $250 million.

  • Default avatar
    John F. Manzello

    Mr. Manzello was appointed President of Promosome in 2007, bringing nearly 20 years of executive and director level experience in the biopharmaceutical industry with a focus on business development and strategic alliances for the introduction of novel technologies.

  • 805bf8c4 3661 485a a3ef bf977198202a
    Senior Vice President & Chief Scientific Officer

    Dr. Mauro investigates fundamental mechanisms of translation initiation. His studies provided the first demonstration of mRNA:rRNA basepairing as a translation initiation mechanism in eukaryotes, and the identification of cis-regulatory elements in mRNAs, which include TEEs. More recently, Dr. Mauro and his colleagues have developed selection methodologies to identify such elements in mammalian cells and in yeast.

  • Ms. Busby has been involved in the venture capital industry as an investor and entrepreneur for over 20 years. Currently, under the moniker Cresco Advisors LLC, Ms. Busby provides a variety of financial and advisory services to fund managers and small businesses, including Promosome LLC.


  • Default avatar
    Intellectual Property - Mintz Levin; Corporate - Curtis Mallet-Prevost